Pharmafile Logo
Pharmafocus logo
Advanced Search

Farydak

Showing 7 posts of 7 posts found.

NICE publishes new myeloma guidance

February 10, 2016
Medical Communications, Research and Development Farydak, Novartis, multiple myeloma

NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …

News
Novartis image

NICE backtracks on Novartis Farydak decision

December 4, 2015
Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat

NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …

News
Farydak

NICE rejects Farydak for multiple myeloma

September 16, 2015
Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat

NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …

News
Farydak

Novartis blood cancer drug Farydak receives EU approval

September 4, 2015
Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

News

FDA in Novartis cancer drug U-turn

February 24, 2015
Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma

The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …

News

Priority review for Novartis myeloma drug

November 26, 2014
Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac

Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …

News

Future bleak for Novartis’ myeloma drug

November 21, 2014
Medical Communications FDA, Farydak, Novartis, ixazomib, myeloma, panobinostat

Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025